Pradžia › Limfoma › Masčusetsas › Boston
Limfoma klinikiniai tyrimai Boston, MA
33 tyrimai dėl Limfoma ieško dalyvių vietose Boston ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Renkami dalyviai1 fazė
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Renkami dalyviai2 fazė
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Renkami dalyviai
- Mass General Hospital, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Renkami dalyviai
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Renkami dalyviai1/2 fazė
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
Renkami dalyviai2 fazė
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Renkami dalyviai1/2 fazė
- Research Site, Boston
- Research Site, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Renkami dalyviai1/2 fazė
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Renkami dalyviai3 fazė
- Research Site, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Renkami dalyviai1/2 fazė
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Renkami dalyviai1/2 fazė
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Renkami dalyviai4 fazė
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
Renkami dalyviai2 fazė
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
Renkami dalyviai2 fazė
- Dana Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Renkami dalyviai1/2 fazė
- Call for Information (Investigational Site 0026), Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Renkami dalyviai1/2 fazė
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Renkami dalyviaiStebimasis tyrimas
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
Renkami dalyviai
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Renkami dalyviai
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Renkami dalyviai1/2 fazė
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Renkami dalyviai
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Renkami dalyviai2 fazė
- Dana-Farber Cancer Institute, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Renkami dalyviai2 fazė
- Beth Israel Deaconess Medical Center, Boston
Odronextamab in Low Tumor Volume Advanced FL
Renkami dalyviai2 fazė
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Renkami dalyviai2 fazė
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Renkami dalyviai2 fazė
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Renkami dalyviai2 fazė
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Renkami dalyviai1 fazė
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Renkami dalyviai
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
Renkami dalyviai1/2 fazė
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Renkami dalyviai1/2 fazė
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Renkami dalyviai2 fazė
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
Renkami dalyviai
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Limfoma tyrimai kituose miestuose
- Houston, TX34 tyrimai
- New York City, NY33 tyrimai
- Washington, DC23 tyrimai
- Baldwin Park, CA21 tyrimas
- Chicago, IL20 tyrimai
- Durham, NC17 tyrimai
- St. Louis, MO15 tyrimai
- Philadelphia, PA15 tyrimai
- Cleveland, OH14 tyrimai
- Edison, NJ12 tyrimai
- Atlanta, GA12 tyrimai
- Seattle, WA12 tyrimai
Kiti tyrimai Boston
- Krūties vėžys111 tyrimai
- Nedidelinių ląstelių plaučių vėžys90 tyrimai
- Vėžys (visų tipų)86 tyrimai
- Storosios ir tiesiosios žarnos vėžys63 tyrimai
- Metastatinis vėžys63 tyrimai
- Plaučių vėžys62 tyrimai
- Kiaušidžių vėžys61 tyrimas
- Prostatos vėžys59 tyrimai
- Depresija52 tyrimai
- Endometrio vėžys50 tyrimai
- Širdies nepakankamumas44 tyrimai
- Ūmi mieloidinė leukemija44 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.